Currently, several investigations have illustrated the potential of CD19/BAFF-R as a novel therapeutic target for cancer [31–34], aligning with our own research findings that CD19 and BAFF-R on B-cells bestow protective properties. This evidence concerns the gene TNFRSF13C and cancer.